ClinicalTrials.gg
CompletedNCT01319903Updated Jan 13, 2012

Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29

A Phase 1 interventional study of CaCP29, a humanized monoclonal antibody in Drug Safety, sponsored by InflaRx GmbH. Completed at 1 site in Germany. Open to male participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-01-13.

Sponsored by InflaRx GmbH · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 141 studies in Sepsis with a site in Germany — 20 open to participants now, 21 under way, none of them phase 3. Sepsis · Germany.

Enrollment
62nd of 69
26 · median 200
Started
2011
with 4 others
Phase 1
3 of 141
1 open now
Registered
41st of 141
by date

Among the 141 studies in Sepsis with a site in Germany, this one is the 62nd largest by enrollment of the 69 interventional ones that give a count, is one of 5 that started in 2011, is one of 3 in phase 1, and was the 41st registered.

Sepsis

2,418 studies on the registry are indexed under Sepsis; 542 are open to participants now.

Browse Sepsis studies →

Open to participants now

20 of the 141 studies in Sepsis with a site in Germany are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 318 Sepsis studies recruiting now, 213 (67%) set no upper age limit and 53 (17%) stop at 75 or younger; 68 take children under 18; 42 take healthy volunteers.

This study: 18 Years to 40 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 141 studies in Sepsis with a site in Germany, or all of them as a file.
02

Study summary

The novel humanized monoclonal antibody CaCP29 was developed to control the inflammatory response to various stimuli in humans and espacially during sepsis. Purpose of this phase I clinical trial in healthy human males is to investigate various parameters concerning safety and tolerability of CaCP29 and assess pharmacokinetic and pharmacodynamic parameters.

Read the detailed description

The acute inflammatory innate host response, as being present during the development of sepsis and various other acute inflammatory diseases, represents a powerful mechanisms which can lead to destruction of host tissue and severe organ dysfunction. CaCP29 was developed to lower the complement mediated acute inflammatory response and thereby control the extend of a strongly activated often times self-destructive inflammatory response by controlling activation of a key inflammatory mechanism.

03

Conditions studied

  • Drug Safety

Keywords

  • sepsis
  • inflammation
  • complement
  • immune system
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male, Caucasian subjects aged between 18-40 years (inclusive)
  • Healthy subjects as determined by medical history, physical examination
  • Body weight between 70 - 100 kg and between 19 and 29 kg/m2, extremes incl
  • recording based on a 12-lead ECG which is normal (PR \< 210 ms, QRS \<110 ms, QTC 380 -430 ms) or contains only slight deviations
  • Normal vital signs (after 5 minutes resting), blood pressure values (systolic > or equal to 100 and \< or equal to 140 mmHg, diastolic > or equal to 50 and \< or equal to 90 mmHg), heart rate between 45 and 90 beats per minute (bpm), body temperature \< 37.5°C
  • Subjects who are able and willing to give written
  • Normal white blood cell count, CRP and IL-6 at screening and Day -1
  • Subjects must be using two acceptable methods for (e.g. spermicide and condom) during the study and refrain from fathering a child in the 3 months following dosing

Exclusion criteria

Exclusion Criteria:

  • In the opinion of the investigator subjects with history or presence of cardiovascular, respiratory, renal, hepatic, metabolic, endocrinological, gastrointestinal, hematological, neurological, dermatological, psychiatric diseases, cancer or other major diseases;
  • Infection or known inflammatory process;
  • Known diseases or immunodeficiency or known family history of autoimmune diseases or immunodeficiency;
  • Clinical significant allergic disease;
  • Known serum hepatitis or who are carriers of the surface antigen or antibodies or with a positive result to the test for 1/2 antibodies;
  • Subjects who have received an drug and/or a vaccination within 3 months prior to start of the treatment in study and those who anticipate receipt of a vaccine within 2 months after the last dose of study drug;
  • Subjects, who have received prior treatment within 1 year with monoclonal antibodies or other biologic agents;
  • The use of any concomitant prescription or non-prescription medication within 14 days prior to the first administration of study medication until follow-up; or treatment with medication that may affect immune function (e.g. immunoglobulins, ) within 6 months before dosing;
  • Donation of blood (>400 ml) or blood products within the last 3 months prior to admission to the clinical unit or plasmapheresis within 4 weeks prior to study start;
  • Definite or suspected personal history of adverse reactions or to drugs especially to the ingredients of the trial compound or to compounds with a similar structure;
  • Use of more than 5 cups or glasses of coffee, tea and / or cola per day;
  • Presence or history of drug and/or alcohol abuse or an average daily intake of more than 20 g alcohol per day;
  • Positive test for alcohol or drugs at screening and/or on Day -1;
  • Smokers of > 5 cigarettes/day or equivalent;
  • Subjects who are unlikely to be compliant and attend scheduled clinic visits as required;
  • Participation in this study on a previous dose level
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
26 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Number and extent of changes in safety relevant parameters after injection of CaCP29

    Safety relevant parameters include changes from baseline of: * cytokine levels over time (IL-6, IL-8, IFN-gamma, TNF-alpha, IL-10) * CH50 activity over time * standard hematology, clinical chemistry and coagulation laboratory parameters * 12-lead ECG * vital signs

    Time frame: pre-dose, days 1,2,3,7,14,28 and 70

Secondary outcomes

  1. Assessment of pharmacokinetic parameters of CaCP29 over time

    * Area under the plasma concentration versus time curve (AUC) of CaCP29 * Peak Plasma Concentration (Cmax) of CaCP29 and time to reach Cmax * terminal phase half-life * clearance * volume of distribution during the terminal phase

    Time frame: pre-dose, day 1,2,3,7, 14, 28 and 70

  2. Number of Participants developing anti-CaCP29 antibodies - Immunogenicity

    Time frame: pre-dose, days 28 and 70

  3. Bioactivity of CaCP29 in human whole blood over time after injection

    Time frame: pre-dose, days 1,2,3,7,14,28 and 70

07

Study locations

1 site
  • FOCUS Clinical Drug Development GmbH
    Neuss, Nordrhein-Westfalen 41460, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2011
First posted
Mar 22, 2011
Start
Mar 2011
Primary completionActual
Oct 2011
CompletionActual
Oct 2011
Last update
Jan 13, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01319903
Lead sponsor
InflaRx GmbH
Responsible party
Sponsor
First posted
Mar 22, 2011
Start date
Mar 2011
Primary completion
Oct 2011
Completion
Oct 2011
Last update
Jan 13, 2012

Study contacts

Grit Andersen, MD
principal investigator · FOCUS Clinical Drug Development GmbH Stresemannallee 6 41460 Neuss Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vilobelimab

Start the discussion